Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $84.3 million.

  • Utah Medical Products' Cash & Current Investments fell 473.14% to $84.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.3 million, marking a year-over-year decrease of 473.14%. This contributed to the annual value of $83.0 million for FY2024, which is 1065.17% down from last year.
  • Latest data reveals that Utah Medical Products reported Cash & Current Investments of $84.3 million as of Q3 2025, which was down 473.14% from $82.2 million recorded in Q2 2025.
  • Utah Medical Products' Cash & Current Investments' 5-year high stood at $93.8 million during Q1 2024, with a 5-year trough of $56.0 million in Q1 2021.
  • For the 5-year period, Utah Medical Products' Cash & Current Investments averaged around $77.3 million, with its median value being $82.2 million (2025).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 4145.1% in 2021, then plummeted by 1117.5% in 2025.
  • Utah Medical Products' Cash & Current Investments (Quarter) stood at $61.0 million in 2021, then rose by 23.09% to $75.1 million in 2022, then rose by 23.74% to $92.9 million in 2023, then dropped by 10.65% to $83.0 million in 2024, then grew by 1.56% to $84.3 million in 2025.
  • Its last three reported values are $84.3 million in Q3 2025, $82.2 million for Q2 2025, and $83.3 million during Q1 2025.